Case report J Neurosurg spine 25:775-781, 2016 E xtracranial meningioma metastases (EMM) occur in 0.1%-0.2% of meningioma cases, with the lungs and pleura being the most common sites followed by liver, lymph nodes, and osseous involvement of long bones and the vertebral column. 3, 5, 15, 17, 19, 24, 36, 38 While rare overall, EMM are more common with atypical (WHO Grade II) or anaplastic (WHO Grade III) meningiomas. 15, 21, 36 Although EMM can complicate treatment and worsen prognosis, no standard of care has been established for management. 17, 19 Recent work has highlighted the clinical, radiological, molecular, and cytogenetic profiles of primary meningiomas that metastasize, but has been focused primarily on EMM to the lungs. 3, 5, 16, 17, 19, 36, 38 In this case report, clinical, radiological, and histopathological findings are presented from 2 patients with meningiomas that metastasized to the spine and vertebral column. Twenty-four additional cases of intraspinal and vertebral EMM in meningiomas were identified in the literature and are also presented. These cases and literature review may aid clinicians in identifying patients with meningiomas that are at risk for spine metastases with appropriate clinical presentation.
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Methods
All patients treated for recurrent atypical/anaplastic meningiomas between January 1985 and July 2014 at Memorial Sloan Kettering Cancer Center were screened. A total of 918 patients were screened, of whom 81 had recurrent disease. For all patients with original pathology reports dated before 2000 or initial surgery performed at an outside institution, the slides were retrospectively reabbreviatioNs EMM = extracranial meningioma metastases; STR = subtotal resection. sUbMitteD December 11, 2015 28 Two patients were identified as having recurrent cranial disease complicated by vertebral or intraspinal EMM and were included in this case report (Table 1) . Inpatient and outpatient charts were reviewed to collect clinical, radiographic, and pathological data. This study was approved by the Institutional Review Board of Memorial Sloan Kettering Cancer Center.
A literature review was also performed. The PubMed database was screened for intraspinal and vertebral EMM cases from 1985 to 2015 using the following key terms: "meningioma intraspinal metastasis," "meningioma intraspinal metastases," "meningioma vertebral metastasis," and "meningioma vertebral metastases."
results

Case 1
A 58-year-old woman with a homogeneously enhancing dural-based mass in the left middle cranial fossa (Fig.  1A ) underwent a Simpson Grade III resection. Tumor histology revealed an atypical meningioma (WHO Grade II) with increased mitotic activity. At 24 months, a large, multicompartmental recurrence infiltrating the orbit and brainstem was treated using subtotal resection (STR) and intensity-modulated radiation therapy with 54 Gy. At 34 months, STR was performed to remove tumor growth extending intracranially and superficially into the soft tissue of the face. At 40 months, the patient experienced worsening radicular pain in the left S-1 distribution without neurological deficit. MRI revealed a large, expansile osseous lesion in the left hemisacrum, narrowing the central canal and encroaching on the neural foramina ( Fig. 1B and C) . Additional lesions were seen in the L-4 and T7-10 vertebral bodies. EMM were confirmed with CT-guided needle biopsy of the sacral lesion, which revealed anaplastic meningioma (WHO Grade III). The patient was offered palliative pain management and died 45 months after initial diagnosis.
Case 2
A 57-year-old woman with a right frontal meningioma (Fig. 2 left) underwent resection at an outside hospital. Tumor histology revealed a benign meningioma (WHO Grade I). At 24 months, a recurrence required STR and postoperative conventional radiation therapy with 54 Gy. At 60 months, a second recurrence underwent resection and intraoperative P-32 brachytherapy with 10 Gy. Tumor histology revealed an atypical meningioma (WHO Grade II). At 72 months, a third recurrence received courses of bevacizumab and hydroxyurea. Shortly after, the patient experienced left upper-extremity and lowback pain. MRI revealed a lytic bone lesion in the distal left clavicle, a small lesion in the proximal left humerus, and multilevel multifocal osseous lesions in the spine (Fig. 2 right) . EMM were confirmed with CT-guided core biopsy of a T-11 vertebral body lesion revealing spindle cell neoplasm with necrosis and positive epithelial membrane antigen immunostaining. Palliative care was provided until the patient's death, 84 months after initial diagnosis.
literature review
A total of 128 articles were screened. The included articles contained histological diagnosis of the primary intracranial meningiomas with vertebral or intraspinal EMM. Histological diagnosis of EMM was not required for inclusion. Nineteen articles met the inclusion criteria, representing 24 cases with 34 vertebral or intraspinal EMM ( Table 2 ). The median age at diagnosis of the primary intracranial meningioma was 51 years (range 14-87 years) with a female predominance (14 females and 10 males). Forty-two percent (10/24) of reported vertebral or intraspinal EMM cases occurred in patients with WHO Grade I primary tumors. The remaining 58% (14/24) of vertebral or intraspinal EMM occurred in higher-grade meningiomas.
The median time to EMM was 78 months (range 3-168 months), with 25% (6/24) of the EMM occurring after the primary tumor, and the remaining 75% (18/24) of EMM occurring after the first recurrence of the primary lesion. Seventy-five percent (18/24) of vertebral or intraspinal EMM presented with symptoms, with pain being the most common symptom. Other presenting symptoms included reduced sensation, paresthesias, lower-extremity weakness, and reduced deep tendon reflexes. Thirty-eight percent (9/24) of vertebral or intraspinal EMM cases had EMM to other organs.
Treatment of the primary intracranial meningioma included surgery alone in 58% (14/24) and surgery plus radiation therapy in 25% (6/24) of cases. Treatment of the primary lesion was unknown in the remaining cases. Treatment of the vertebral or intraspinal EMM varied, but generally included surgery alone, radiation therapy alone, surgery plus radiation therapy, or chemotherapy. 
Discussion
Meningiomas account for 15%-35% of all primary intracranial and intraspinal tumors, with 70%-80% being benign (WHO Grade I) on histopathological grading. 41 Atypical and anaplastic meningiomas together account for a significant minority of all intracranial meningiomas and display an aggressive clinical behavior, including high rates of recurrence. Atypical meningiomas (WHO Grade II) show 4 or more mitotic figures per 10 hpf, or express 3 or more atypical features such as hypercellularity, necrosis, cell pleomorphism, and brain invasion. Anaplastic meningiomas (WHO Grade III) have 20 or more mitotic figures per 10 hpf or lack of differentiation with a carcinomatous or sarcomatous-like appearance. WHO Grade II meningiomas can be further subtyped into chordoid and clear cell, while WHO Grade III meningiomas can be further subtyped as papillary or rhabdoid.
Atypical and anaplastic meningiomas (WHO Grade II and Grade III) are associated with higher rates of recurrence and metastases, and consequently have poor clinical outcome. 35, 37 In this case report, one patient had an initial diagnosis of atypical meningioma (WHO Grade II), while the other patient had a WHO Grade I meningioma that recurred with atypical histology. High-grade meningiomas that progress from low-grade tumors may have a different clinical course than high-grade meningiomas that arise de novo, but any potential differences are not fully characterized at present.
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While the per case incidence of EMM is low, intracranial meningiomas are common and knowledge of EMM is clinically useful. Forty-two percent (10/24) of reported vertebral or intraspinal EMM cases identified in the literature review occurred in patients with WHO Grade I primary tumors, challenging the notion that EMM are seen mostly in atypical/anaplastic meningiomas. Given this surprising finding, it may be clinically useful to closely follow low-grade meningioma patients as regularly as high-grade meningioma patients with radiological imaging and clinical examinations to identify vertebral and intraspinal EMM.
Time to EMM can vary from a few months to several years. 19, 29, 36, 37 In the presented case reports, time to vertebral or intraspinal EMM ranged from 40 to 74 months. The median time to vertebral or intraspinal EMM in the literature review was 78 months and ranged from 3 months to 14 years. In the case reports, EMM occurred after the last recurrence. Surprisingly, in the literature review 25% (6/24) of vertebral and intraspinal EMM occurred after the primary tumor and prior to any recurrence, which challenges the notion that EMM is an endstage phenomenon in disease progression. In 4 of these 6 cases, the primary tumor was high grade, suggesting that perhaps high-grade meningiomas tend to metastasize earlier than low-grade meningiomas. Therefore, clinical suspicion for vertebral and intraspinal EMM may be warranted not only after meningioma recurrence, but also after the primary tumor, especially in high-grade meningiomas.
While the majority of meningioma cases tend to have EMM to one organ, as many as 31% of cases can have EMM to multiple organs. 37 In total, 6 EMM were identified between the 2 cases presented, with EMM occurring in different organs in one of the cases. The most common site of EMM in the literature is lung (37.2%), followed by bones (16.5%), intraspinal (15.2%), and the liver (9.2%). 5, 12, 16, 17, 37, 38 In the case reports, several EMM were noted in the vertebral bodies, spinal cord, and other bones. In the literature review, 38% (9/24) of vertebral or intraspinal EMM cases had EMM to other organs. Therefore, if vertebral or intraspinal EMM are suspected and identified, whole-body imaging may be recommended to screen for EMM to other organs.
In the case reports, EMM were identified after the patient presented with symptoms, usually pain localized to the EMM. In the literature review, the majority (18/24) of vertebral or intraspinal EMM cases were identified after the patient presented with symptoms, usually pain with associated neurological impairment. Contrarily, in a recent literature review of EMM cases, Surov et al. found that 31.3% of EMM were clinically silent and were discovered incidentally. 37 However, since Surov et al. assessed all EMM cases, their findings may be true of EMM in general, but not representative of vertebral or intraspinal EMM specifically. Given the anatomical location of EMM in the vertebrae or spine, the patient is more likely to have associated symptoms. Treated meningioma patients should therefore be advised to promptly undergo follow-up if they experience back pain, loss of sensation in extremities, loss of muscle tone, or muscular spasms, as these could indicate an underlying vertebral or intraspinal EMM.
Identifiable risk factors for EMM include previous craniotomy, venous sinus invasion, local recurrences, and histological malignancy, namely, papillary morphology, hypercellularity, cellular heterogeneity, high mitotic activity, nuclear pleomorphism, and necrosis. 1, 15, 18, 19, 38 While our 2 patients had most of the identifiable risk factors for EMM, the literature review brings these risk factors under question as applied specifically to vertebral or intraspinal EMM. Notably, a significant number of cases of vertebral or intraspinal EMM occurred in patients with WHO Grade I meningiomas, and EMM occurred in patients prior to any tumor recurrence.
While the exact route of metastasis is unknown, hematogenous, lymphatic, and CSF routes, along with seeding from resection, have been suggested. [6] [7] [8] 14 It is appealing to suspect that CSF spread may account for intraspinal EMM and hematogenous spread for vertebral EMM; however, this is difficult to validate without further laboratory investigation. Recent work has also highlighted several molecular and cytogenetic markers that may predict EMM. Scognamiglio and colleagues reported high expression of CD90 in cases of EMM. 36 CD90, a protein associated with aberrant activation of the self-renewal machinery that is normally restricted to stem cells, has been previously observed in glioblastomas and may play a role in the formation of tumor vasculature and tumor progression, making it a potential marker for meningioma metastatic potential. 23, 34 Using a comparative cytogenetic analysis, Frydrychowicz and colleagues reported deletions affecting chromosomes 22 and 1 in primary atypical meningiomas and their EMM, arguing that chromosomal instability may be associated with metastatic spread.
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Conclusions
This case report and literature review highlight that vertebral and intraspinal EMM can occur in patients with WHO Grade I meningiomas and can occur before tumor recurrence. Unlike EMM to other organs, vertebral and intraspinal EMM are usually symptomatic. Therefore, patients with low-grade and high-grade meningiomas should be followed regularly with imaging after primary tumor treatment for accurate and timely identification of vertebral and intraspinal EMM. Furthermore, patients should be advised to undergo follow-up if they begin experiencing symptoms suggestive of vertebral or intraspinal EMM, 
